Harvard Bioscience - HBIO Stock Forecast, Price & News

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. KeyCorp dropped their price objective on Harvard Bioscience from $10.00 to $7.00 and set an "overweight" rating for the company in a research note on Friday, August 5th. TheStreet cut Harvard Bioscience from a "c" rating to a "d+" rating in a research note on Monday, May 23rd.

Harvard Bioscience Trading Down 0.3 %

Shares of NASDAQ:HBIO traded down $0.01 during trading on Friday, reaching $3.28. The stock had a trading volume of 142,470 shares, compared to its average volume of 219,722. Harvard Bioscience has a fifty-two week low of $3.23 and a fifty-two week high of $8.75. The company has a market cap of $136.57 million, a P/E ratio of -36.55 and a beta of 1.71. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.16 and a current ratio of 2.42. The business's 50-day moving average price is $3.68 and its 200-day moving average price is $4.76.

Harvard Bioscience (NASDAQ:HBIO - Get Rating) last released its earnings results on Wednesday, August 3rd. The medical instruments supplier reported $0.02 EPS for the quarter, topping the consensus estimate of $0.01 by $0.01. Harvard Bioscience had a positive return on equity of 7.74% and a negative net margin of 3.03%. The firm had revenue of $29.21 million during the quarter, compared to analysts' expectations of $30.10 million. On average, equities research analysts predict that Harvard Bioscience will post 0.05 EPS for the current fiscal year.